PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

Mr. Olivier  Ludemann-Hombourger

Director Global Innovation & Technology

Mr. Juan Jose Gonzalez

Chief Executive Officer

Rene  Vestergaard

Director of Corporate Finance

Mr. Jens  Fricke

Director of Global Operations

Mr. Marc  Augustin

Chief Financial Officer

Dr. Klaus Peter Wilden

Executive Chair

Ms. Christina  Del Vecchio

General Counsel & Corporate Secretary

Ms. Monika  Casanova

Chief Human Resources Officer

Mr. Neil James Thompson

Director of Global Sales & Marketing

Christophe  Chevalier

Head of Technical Department - Braine

PolyPeptide Group AG

PolyPeptide Group AG Ledningsstruktur

Information om ledningen